Market Size (2014)
2014
$2.36B
Vertical: HealthcareBase Year: 201611 Sections
Market Size (2014)
2014
$2.36B
Projected (2023)
2023
$4.88B
CAGR (2014–2023)
8.4%
8.4%Key Players
106+
This report covers Insulin Pumps Market with forecasts from 2014 to 2023. 106 key companies are profiled.
The Insulin Pumps Market market is projected to grow at a CAGR of 8.4% from 2014 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansContinuous subcutaneous insulin or the insulin pump has picked up popularity and advancement as a physiologic programmable technique for insulin delivery which is adaptable and lifestyle friendly. Furthermore, the introduction of constant observing with glucose sensors gives exceptional access, and forecast of, a patient's blood glucose levels. Research and development are in progress to coordinate the two technologies, from "sensor-augmented" and "sensor-driven" pumps to a completely automated and independent sensing and delivery system. Despite the fact that endocrinologists and diabetes authorities will keep on maintaining expertise in this field, it becomes essential for physicians to have a learning of insulin pumps and sensors to guarantee ideal clinical care and decision-making for their patients.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2016
Historical Period
2014 – 2016
Forecast Period
2016 – 2023
Primary Interviews
150+
Historical data (2014–2016) and forecast period (2016–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Buyers
The bargaining power of buyers in the insulin pumps market is medium. The market has a reasonable number of buyers, which include physicians, independent and device stores, research laboratories and patients. The existence of buyers in the market is high due to an increasing aging population, the rise in the prevalence of diabetes and lifestyle associated diseases. In addition, buyers are price sensitive, which discreetly affects bargaining power in the market. The insulin pumps market is characterized by a moderate degree of brand identity. Thus, brand plays an important role in the market, as buyers are moderately inclined towards recognized insulin pump manufacturers. In addition, switching cost is moderate for buyers, as pumps are cost-effective and are easily available in the market.
Bargaining Power of Suppliers
Bargaining power of suppliers in insulin pumps market is low to medium. Numbers of suppliers in the market are moderate which leads to the average bargaining power of suppliers. Another factor affecting the bargaining power of suppliers is the reasonable supplier switching cost for buyers. In addition, the low availability of substitutes moderately increases the bargaining power of suppliers. On the other hand, low chances of forwarding integration decrease the bargaining power of suppliers in the global insulin pumps market.
The Threat of New Entrants
The threat of new entrants is medium for the insulin pumps market. Any insulin pump manufacturing company trying to enter the market is required to follow strict regulatory standards to enter the industry. Moderate level of capital requirement is also a major barrier of entry for new players. The insulin pumps market is also characterized by a moderate degree of brand loyalty globally.
Rivalry
The degree of competition in the global insulin pump market is medium to high. The moderate grade of product differentiation among existing players, as insulin pumps are moderately expensive compared to various devices. Thus, this would increase the intensity of rivalry in the market. In addition, brand loyalty moderately affects the market, as buyers are moderately inclined towards established device manufacturers in the global insulin pumps market.
Threat of Substitutes
The threat of substitutes in the global insulin pumps market is medium to high. Substitutes, such as traditional methods, Self-Monitoring of Blood Glucose (SMBG) pose a moderate threat to the insulin pumps market; primarily due to their low cost. Buyers’ propensity towards the substitute is moderate. Thus, the availability of insulin pumps in rural areas is low due to poor healthcare infrastructure and high cost. In addition, the moderate degree of switching cost further minimizes the threat of substitute in the global insulin pumps market.
Market estimates by geography (2023)
InsightNorth America leads with $2.22B by 2023, while Asia Pacific is projected to grow fastest at a 8.7% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2014 | 2016 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $87.20M | $99.90M | $103.70M | 1.9% | 2% |
| North America | $1.05B | $1.59B | $2.22B | 8.6% | 46% |
| Asia Pacific | $382.00M | $580.80M | $811.70M | 8.7% | 17% |
| Europe | $834.60M | $1.26B | $1.74B | 8.5% | 36% |
| Total | $2.36B | $3.53B | $4.88B | 8.4% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$4.88B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Traditional insulin pump | $3.43B | 8.4% | 85% |
| Disposable insulin pump | $1.45B | 8.4% | 82% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Insulin Pumps Market covering market dynamics, competitive landscape, and strategic outlook.
The Insulin Pumps Market market is projected to reach $4.88B by 2023, growing at 8.4% CAGR. The Traditional insulin pump segment holds the largest share.
Diabetes is a chronic disease and its global prevalence is increasing. It is one of the foremost causes of death and generates an increased risk of developing a number of serious health problems such as cardiovascular diseases, kidney diseases, eye disorders, stroke, and others.
The fact-sheet of the World Health Organization in 2017 stated that the global prevalence of diabetes among adults (18 years or more) has risen from 4.7% in 1980 to 8.5% in 2014. Likewise, according to the International Diabetes Federation (IDF) in 2013, ~592 million people are expected to suffer from diabetes by 2035.
In the presence of such trends for increasing diabetic population, a majority of the cases are estimated to be reported for the adult population aging 60 years or more. Thus, with the increasing number of diabetic patients, the demand for insulin devices is expected to grow parallelly and provide suitable backgrounds for the market to grow.
Continuous testing of the glucose level is needed to avoid risks associated with insulin delivery devices. For example, the glucose level in insulin pumps is checked continuously to find if the tubing or cannula is disconnected or blocked. It may lead to various disadvantages and risks associated with the device, such as ketoacidosis due to breakdown or absorption problem, and skin infection at the catheter site. The risk of hypoglycemia, the risk of diabetic ketoacidosis (DKA) from pump malfunction or absorption problems, cost issues as pumps are expensive, and the continuing cost of supplies etc. are some of the risks and disadvantages associated with insulin pumps and are restraining the growth of the global insulin pumps market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 106 companies operating in the Insulin Pumps Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Insulet Corporation
Established in 2000 and headquartered in Billerica, MA United States, Insulet Corporation is one of the leading insulin device companies in the US which is dedicated to making the lives of diabetic patients easier through one of its major products, named Omnipod Insulin Management System. The company’s major motive is to expand the use of insulin pumps among patients who are dependent on insulin pumps.
F. HOFFMANN-LA ROCHE LTD
Incorporated in 1896 and headquarters in Basel, Switzerland; F. Hoffmann-La Roche AG is the world's biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is additionally the world pioneer in vitro diagnostics and tissue-based cancer diagnostics, and a leader in diabetes management. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The products offered by the company helps in tapping in the world’s two third of all the diseases which are either not treated effectively or not treated at all. The company offers various products in the Pharmaceutical, Diagnostics and research industry. Geographically the company operates in North America, Europe, South America, Africa, Asia and Oceania. As of 2015 F. Hoffmann-La Roche AG had a head count of 91,700 + employees world wide Roche Strategy – a methodology that intends to fit the right treatment to every patient in the most ideal way that could be available dedicated on developing innovative diagnostic tests and medicines which will help their patients and the world.
SANOFI
Sanofi is a UK-based global life sciences company which was incorporated in the year 2004. Sanofi is headquartered in Paris having the employee strength of more than 110,000 spread in more than 100 countries and have industrial sites in more than 40 countries. The company is committed to improve the access to healthcare and support the people to whom it serves throughout the continuum of care. Further, the company has its offerings into healthcare solutions, human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. Sanofi CEPiA is a subsidiary business unit of Sanofi that produces articaine hydrochloride in API form. It is a market leader in producing articaine hydrochloride. The company manufactures articaine hydrochloride in its high capacity FDA approved workshop. Sanofi’s Ankleshwar production plant has an export sales of Rs. 54,900 lakhs that is around 27% of their total sales in India in 2015 . Their healthcare solutions are available in more than 170 countries across the world and now Sanofi is focussing on increasing its presence in emerging countries. Their industrial network, know-how and employees deliver a wide range of health solutions to millions of individuals with high quality and safety. Some of the top competitors of Sanofi are Pfizer Inc., Merck & Co., Inc. GlaxoSmithKline Plc., Septodont, Dentsply Sirona, and Pierrel S.p.A., among others.
MEDTRONIC PLC
Company Headquarters: Dublin, Ireland Founded: 1949 Workforce: ~91,000 Company Working: Medtronic plc (Medtronic) is a global healthcare solutions company that focuses on improving the lives of people through medical technologies, solutions, and services. The company with Covidien has accelerated and advanced its abilities to create meaningful innovations for hospitals, health systems, and healthcare providers. The company’s businesses majorly fall into four groups: the Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group, and the Minimally Invasive Therapies Group (MITG). Medtronic operates from over 370 locations in almost 160 countries. The company has been at the forefront of the cardiac telemedicine industry with patented technologies such as ambulatory devices with unified analysis & reporting software and on-site diagnostic systems. The company is committed to advancing science in patient monitoring. The company is awarded more than 4,600 patents.
B. BRAUN MELSUNGEN AG
Established in 1839 and headquartered in Germany, B.Braun is a leading healthcare supplier. The company provides its products for hospitals, surgeries, private practices (medical care and doctors´ offices), and extracorporeal blood treatments. The company’s product segments include clinical nutrition, urinary care, infection prevention, insulin therapy, diabetes care, neurosurgery, extracorporeal blood treatment, IV drugs, orthopaedics, spine, and wound care, amongst others. B.Braun operates in four major divisions, namely, Hospital Care, Aesculap, Out Patient Market, and B. Braun Avitum. With these four divisions, the company has a wide range of products with about 5,000 products, out of which 95% of the products are manufactured by the company. Geographically the company operates in 64 countries in regions such as Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The company generated a revenue of about USD 6672 million in 2015 with a head count of more than 55,000 employees all around the globe.
ABBOTT LABORATORIES
Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:8.0pt; mso-para-margin-left:0cm; line-height:107%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Roboto Condensed"; mso-ascii-font-family:"Roboto Condensed"; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:"Roboto Condensed"; mso-hansi-theme-font:minor-latin; mso-ansi-language:EN-US; mso-fareast-language:EN-US;} Company Headquarters: Illinois, US Founded: 1888 Workforce: ~103,000 Company Working: Abbott Laboratories is engaged in the research, manufacture, and sale of branded generic pharmaceuticals, nutritional products, medical devices, and diagnostics. The company operates in the US, the Netherlands, Germany, Japan, Italy, France, Canada, the UK, and Spain. The four major segments of the company are nutritionals, diagnostics, established pharmaceutical products, and cardiovascular & neuromodulation, and others. The nutritional segment of the company includes a broad line of pediatric and adult nutritional products. The nutritionals segment also includes nutritional products used in enteral feeding in healthcare institutions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Insulin Pumps Market